These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8883232)

  • 1. A double-blind, placebo-controlled trial of i.v. dolasetron mesilate in the prevention of radiotherapy-induced nausea and vomiting in cancer patients.
    Bey P; Wilkinson PM; Resbeut M; Bourdin S; Le Floch O; Hahne W; Claverie N
    Support Care Cancer; 1996 Sep; 4(5):378-83. PubMed ID: 8883232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study.
    Korttila K; Clergue F; Leeser J; Feiss P; Olthoff D; Payeur-Michel C; Wessel P; Nave S; Hahne W; Brown R
    Acta Anaesthesiol Scand; 1997 Aug; 41(7):914-22. PubMed ID: 9265937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
    Chevallier B; Cappelaere P; Splinter T; Fabbro M; Wendling JL; Cals L; Catimel G; Giovannini M; Khayat D; Bastit P; Claverie N
    Support Care Cancer; 1997 Jan; 5(1):22-30. PubMed ID: 9010986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery.
    Diemunsch P; D'Hollander A; Paxton L; Schoeffler P; Wessel P; Navé S; Brown RA; Hahne WF
    J Clin Anesth; 1997 Aug; 9(5):365-73. PubMed ID: 9257201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
    Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
    Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
    Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
    J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral dolasetron mesylate for prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. The Oral Dolasetron PONV Prevention Study Group.
    Diemunsch P; Korttila K; Leeser J; Helmers JH; Wilkey B; Navé S; Radke AJ; Hahne WF; Brown RA
    J Clin Anesth; 1998 Mar; 10(2):145-52. PubMed ID: 9524901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting.
    Diemunsch P; Leeser J; Feiss P; D'Hollander A; Bradburn BG; Paxton D; Whitmore J; Panouillot P; Navé S; Brown RA; Hahne WF
    Can J Anaesth; 1997 Feb; 44(2):173-81. PubMed ID: 9043731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting.
    Fauser AA; Pizzocaro G; Schueller J; Khayat D; Wilkinson P
    Support Care Cancer; 2000 Jan; 8(1):49-54. PubMed ID: 10650898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral dolasetron mesilate (MDL 73,147EF) for the control of emesis during fractionated total-body irradiation and high-dose cyclophosphamide in patients undergoing allogeneic bone marrow transplantation.
    Fauser AA; Russ W; Bischoff M
    Support Care Cancer; 1997 May; 5(3):219-22. PubMed ID: 9176968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prophylaxis of nausea and vomiting after thyroid surgery: comparison of oral and intravenous dolasetron with intravenous droperidol and placebo].
    Danner K; Becker HG; Best B; Madler C
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2001 Jul; 36(7):425-30. PubMed ID: 11496617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group.
    Fauser AA; Duclos B; Chemaissani A; Del Favero A; Cognetti F; Diaz-Rubio E; Cortes-Funes H; Conte PF; Dressler H
    Eur J Cancer; 1996 Aug; 32A(9):1523-9. PubMed ID: 8911112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of postoperative nausea and vomiting with single intravenous doses of dolasetron mesylate: a multicenter trial. Dolasetron Mesylate PONV Treatment Study Group.
    Kovac AL; Scuderi PE; Boerner TF; Chelly JE; Goldberg ME; Hantler CB; Hahne WF; Brown RA
    Anesth Analg; 1997 Sep; 85(3):546-52. PubMed ID: 9296407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolasetron for the prevention of postoperative nausea and vomiting following outpatient surgery with general anaesthesia: a randomized, placebo-controlled study. The Dolasetron PONV Prevention Study Group.
    Philip BK; Pearman MH; Kovac AL; Chelly JE; Wetchler BV; McKenzie R; Monk TG; Dershwitz M; Mingus M; Sung YF; Hahne WF; Brown RA
    Eur J Anaesthesiol; 2000 Jan; 17(1):23-32. PubMed ID: 10758440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide.
    Hesketh PJ; Gandara DR; Hesketh AM; Facada A; Perez EA; Webber LM; Martin LA; Cramer MB; Hahne WF
    Support Care Cancer; 1996 Mar; 4(2):141-6. PubMed ID: 8673351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials.
    Whitmore JB; Kris MG; Hesketh PJ; Grote TH; DuBois DM; Cramer MB; Hahne WF
    Support Care Cancer; 1998 Sep; 6(5):473-8. PubMed ID: 9773466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.
    Harman GS; Omura GA; Ryan K; Hainsworth JD; Cramer MB; Hahne WF
    Cancer Chemother Pharmacol; 1996; 38(4):323-8. PubMed ID: 8674154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery.
    Graczyk SG; McKenzie R; Kallar S; Hickok CB; Melson T; Morrill B; Hahne WF; Brown RA
    Anesth Analg; 1997 Feb; 84(2):325-30. PubMed ID: 9024022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy. Oral Dolasetron Dose-Response Study Group.
    Rubenstein EB; Gralla RJ; Hainsworth JD; Hesketh PJ; Grote TH; Modiano MR; Khojasteh A; Kalman LA; Benedict CR; Hahne WF
    Cancer; 1997 Mar; 79(6):1216-24. PubMed ID: 9070501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic oral dolasetron mesylate reduces nausea and vomiting after abdominal hysterectomy. The Canadian Dolasetron Study Group.
    Warriner CB; Knox D; Belo S; Cole C; Finegan BA; Perreault L
    Can J Anaesth; 1997 Nov; 44(11):1167-73. PubMed ID: 9398956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.